A Phase 1 interventional study of Beta-hCG in Azoospermia, Nonobstructive, sponsored by Egymedicalpedia. Completed at 1 site in Egypt. Open to male participants aged 19 Years to 72 Years. Per ClinicalTrials.gov, last updated 2023-10-19.
Sponsored by Egymedicalpedia · Phase 1, Interventional, and Treatment
Urologists and reproductive specialists are often challenged when facing patients with severe male infertility scenarios. In particular, the treatment of men with NOA demands a deeper insight. In such cases, .
The hormonal stimulation of spermatogenesis is still being explored. Thus, there is still little knowledge regarding the type of patient who might benefit from medical treatment, the optimal medication,
the regimen, and the duration of treatment. In male infertility, the induction for treatment with follicle stimulating hormone (FSH) in the induction and maintenance of spermatogenesis in patient with hypogonadotopic hypogonaism. As these patients are normally azoospermic without gonadotropin stimulation and during testosterone therapy
The presence of high numbers of progressively motile and normally formed sperms in the ejaculate during exogenous gonadotropin therapy might result in the desired clinical pregnancy for many infertile couples on an experimental basis and in some places already in clinical routine. FSH preparation are also used for treatment of normogonadotopic infertile men with idiopathic impairment of spermatogemesis.
Pulstile GnRH or exogenous gonadotropins are usually used to induce spermatogenesis and promote testicular enlargement .The regimen for gonadotropin replacement includes an initial use of human chorionic gonadotropin (HCG) for 6 to 12 months and then addition of FSH or human menopausal gonadotropins (HMG) until pregnancy
23 studies on the registry are indexed under Azoospermia, Nonobstructive; 7 are open to participants now.
This study's enrollment of 100 is above the median of 61 across 12 interventional studies indexed under Azoospermia, Nonobstructive.
Browse Azoospermia, Nonobstructive studies →Egymedicalpedia is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Administration of hormonal therapy (as Beta HCG (5000 IU I.M) twice weekly for three months
Drug: Beta-hCG
Administration of L-carnitine 1000 mg twice daily for three months
Drug: Beta-hCG
Treatment of spermatogenesis
Hormonal treatment
About 100 participants receiving Beta HCG (5000 IU I.M) twice weekly to evaluate the effect of hormonal stimulation for patients with non-obstructive azoospermia
Time frame: from baseline up to 3 months after the treatment day.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.